Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.

Background: The PORTEC-3 trial investigated the benefit of chemoradiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We present the preplanned long-term analysis of the randomised PORTEC-3 trial with a post-hoc analysis including molecular classification of the tumours.

Methods: PORTEC-3 was an open-label, multicentre, randomised, international phase 3 trial.

Competing risks models with two time scales.

Competing risks models can involve more than one time scale. A relevant example is the study of mortality after a cancer diagnosis, where time since diagnosis but also age may jointly determine the hazards of death due to different causes. Multiple time scales have rarely been explored in the context of competing events.

A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment.

Background: A substantial proportion of gastric cancer patients develop severe treatment-related toxicity, significantly impacting health-related quality of life. The primary aim of this study was to identify distinct toxicity clusters of gastric cancer patients. The secondary aims were to assess whether cluster membership was associated with event-free (EFS) and overall survival (OS).

Nonparametric Estimation of Transition Intensities in Interval-Censored Markov Multistate Models Without Loops.

Interval-censored multistate data is collected when the state of a subject is observed periodically. The analysis of such data using nonparametric multistate models was not possible until recently but is very desirable as it allows for more flexibility than its parametric counterparts. The single available result to date has some unique drawbacks.

Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy.

Introduction: Hematologic toxicity (HT) is a common effect of chemoradiotherapy in primary locally advanced cervical cancer (LACC) and related to bone marrow (BM) fat increase. However, longitudinal effects and dose-relationships are unknown. In this study, pre- and post-treatment BM fat fraction and blood immune cell counts were evaluated in women with primary LACC undergoing BM sparing chemoradiotherapy.